RNA sequencing of chronic GVHD skin lesions defines shared and unique inflammatory pathways characterizing lichen planus and morphea.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
10 05 2022
10 05 2022
Historique:
received:
10
03
2021
accepted:
12
12
2021
pubmed:
11
1
2022
medline:
7
5
2022
entrez:
10
1
2022
Statut:
ppublish
Résumé
Cutaneous involvement of chronic graft-versus-host disease (cGVHD) has a wide range of manifestations including a lichenoid form with a currently assumed mixed Th1/Th17 signature and a sclerotic form with Th1 signature. Despite substantial heterogeneity of innate and adaptive immune cells recruited to the skin and of the different clinical manifestations, treatment depends mainly on the severity of the skin involvement and relies on systemic, high-dose glucocorticoids alone or in combination with a calcineurin inhibitor. We performed the first study using RNA sequencing to profile and compare the transcriptome of lichen planus cGVHD (n = 8), morphea cGVHD (n = 5), and healthy controls (n = 6). Our findings revealed shared and unique inflammatory pathways to each cGVHD subtype that are both pathogenic and targetable. In particular, the deregulation of IFN signaling pathway was strongly associated with cutaneous cGVHD, whereas the triggering receptor expressed on myeloid cells 1 pathway was found to be specific of lichen planus and likely contributes to its pathogenesis. The results were confirmed at a protein level by performing immunohistochemistry staining and at a transcriptomic level using real-time quantitative polymerase chain reaction.
Identifiants
pubmed: 35008096
pii: 483408
doi: 10.1182/bloodadvances.2021004707
pmc: PMC9092416
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2805-2811Informations de copyright
© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Références
Front Immunol. 2018 May 02;9:963
pubmed: 29770141
J Allergy Clin Immunol. 2015 May;135(5):1218-27
pubmed: 25840722
Innate Immun. 2012 Apr;18(2):250-7
pubmed: 21690199
Immunol Lett. 2008 Mar 15;116(2):111-6
pubmed: 18192027
Pharmacol Ther. 2017 Sep;177:81-95
pubmed: 28245991
J Immunol. 2018 Jan 1;200(1):139-146
pubmed: 29187588
N Engl J Med. 2017 Dec 28;377(26):2565-2579
pubmed: 29281578
Bone Marrow Transplant. 2015 Dec;50(12):1563-71
pubmed: 26367225
J Am Acad Dermatol. 2020 Sep;83(3):824-831
pubmed: 31404571
Bone Marrow Transplant. 2018 Jul;53(7):832-837
pubmed: 29367715
Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1
pubmed: 25529383
Clin Exp Immunol. 2008 Apr;152(1):88-94
pubmed: 18321350
Clin Cancer Res. 2007 Oct 15;13(20):6107-14
pubmed: 17947475
Nat Rev Immunol. 2012 May 25;12(6):403-16
pubmed: 22627859
J Invest Dermatol. 2013 Jul;133(7):1742-51
pubmed: 23407402
J Immunol. 2016 Nov 1;197(9):3490-3503
pubmed: 27694491
Blood. 2012 Nov 15;120(20):4246-55
pubmed: 23012327
Biol Blood Marrow Transplant. 2010 Jan;16(1 Suppl):S146-51
pubmed: 19836455
J Clin Oncol. 2016 Aug 1;34(22):2583-90
pubmed: 27217465
Cell. 2008 May 30;133(5):775-87
pubmed: 18510923
Blood. 2015 Mar 12;125(11):1703-7
pubmed: 25645355
Biol Blood Marrow Transplant. 2017 Feb;23(2):211-234
pubmed: 27713092
Expert Opin Ther Pat. 2014 Dec;24(12):1383-95
pubmed: 25363248
Blood. 2014 Jan 9;123(2):290-9
pubmed: 24255916
J Immunol. 2008 Aug 1;181(3):2211-9
pubmed: 18641361